2024 American Association for Cancer Research Annual Meeting

Schedule of DCTD Presentations

DCTD-supported research will be presented at the AACR Annual Meeting from April 5-10, 2024.

The following tables include presentations containing DCTD staff speakers and co-authors.

• Oral Presentations
• Poster Presentations
• Meet-the-Expert Presentations
• Staff Kiosk Schedule

Oral Presentations

Date/Time	Title/DCTD Speaker (If Applicable)	ID
April 6 2:35-2:55 pm	Concepts in the design and analysis of COMBO MATCH /James H. Doroshow	MW08
April 7 3:35-3:50 pm	MTX-531, a first-in-class pan-PI3K inhibitor spares hyperinsulinemia yielding durable tumor regressions and resilience to adaptive resistance	1230
April 8 1:30-2:30 pm	NCI Funding Opportunities and Grant Writing Strategies for New and Early-Stage Investigators /Morgan O’Hayre; Sundar Venkatachalam; Christophe Marchand	NIH06
April 9 2:30-3:30 pm	NCI’s Childhood Cancer Data Initiative: Building on the Power of Data and Community /Gregory Reaman; Malcolm Smith; Ana Robles	NIH10

Poster Presentations

Date/Time	Title/DCTD Presenter (If Applicable)	ID
April 7 1:30 PM - 5:00 PM	Multi-omic analysis of allelic expression patterns of imprinted and non-imprinted genes in cancer and their association with drug response Julia Krushkal	862/6
	An evaluation of patritumab deruxtecan (HER3-DXd, U3-1402) against pediatric PDX models for hepatoblastoma and rhabdomyosarcoma - A report from the NCI PIVOT Program	1088/9
April 8 9:00 AM - 12:30 PM	A pro-oncogenic RAS-GTP:RAN-GAP complex facilitates nuclear protein export and has clinical implications	2089/13
	5-Aza-4'-thio-2'-deoxycytidine induces C to G transversions in a specific trinucleotide context and leads to acute lymphoid leukemia	1484/22
	The ROR1 antibody-drug conjugate, MK-2140, enhances the efficacy of established drugs in preclinical models of pediatric acute lymphoblastic leukemia	1905/16
April 8 1:30 PM - 5:00 PM	Polymerase θ (POLθ) inhibitors (novobiocin, ART-558, RP6685) were tested with 22 approved and investigational agents in multi-cell type spheroids of genetically selected patient-derived human tumor cell lines Beverly Teicher	LB215 / 10
	Development and performance of the National Cancer Institute’s HTS384 NCI60 screen: A modernized platform to support drug discovery and development by the worldwide cancer research community	3090/1
	Phase 1 trial of bortezomib and clofarabine combination in adults with refractory solid tumors Andre De Souza	CT120/28
	Conservation of JAK-STAT signaling in canine lymphocytes responding to human IL-6, IL-7, and IL-1 alpha	2837/24
April 9 9:00 AM - 12:30 PM	Combinations of Cdc-like kinase (CLK) inhibitors with targeted oncology agents or standard chemotherapy in patient-derived multi-cell type tumor spheroids	4608/6
	Evaluation of the prevalence and impact of molecular variation in the three-prime repair exonuclease 1 TREX1 across mammalian species and in human malignancies Mariam Konate	4345/15
April 9 1:30 PM - 5:00 PM	Atezolizumab clinical trial biopsies reveal varied immune landscapes in clear cell sarcoma and chondrosarcoma	CT263/22
	Upregulation of TET2 expression by DNA methyltransferase (DNMT) inhibitors is associated with resistance in DNMT1 knockout colorectal cancer cells Sherry Yang	5881/25
	Interleukin-1 upregulates dual oxidase 2 expression and ROS production in human pancreatic cancer cells David Mallick	5327/7
April 10 9:00 AM - 12:30 PM	Cholangiocarcinoma patient-derived models in the NCI Patient-Derived Models Repository	6898/9
	Expanding reported molecular characteristics for the NCI Patient-Derived Models Repository	6911/2
	Genomic landscape and stability of preclinical models in NCI's patient-derived models repository	6914/25
	Integrated proteogenomic analysis for the NCI patient-derived cancer model repository	6915/26
	In vivo efficacy of anti-B7-H3 antibody-drug conjugate (ADC) ifinatamab deruxtecan (I-DXd; DS-7300): An update from the Pediatric Preclinical In Vivo Testing (PIVOT) Program	LB402/3

Meet-the-Expert Presentations

Date/Time	Topic	Presenter
April 07 3:00 pm	Early-Stage Investigator Policy & R37 Extension Process	Aniruddha Ganguly, Ph.D. Cancer Diagnosis Program
April 07 4:30 pm	NCI Drug Development Resources: NExT, Stepping Stones, and Consultation Service	Morgan O’Hayre, Ph.D. Sharad Verma, Ph.D. Developmental Therapeutics Program
April 08 11:00 am	Developmental Therapeutics Program Services and Repositories	Christophe Marchand, Ph.D. Developmental Therapeutics Program
April 08 1:30 pm	Program Project (P01) Grant Development Guidance	Aniruddha Ganguly, Ph.D. Cancer Diagnosis Program
April 09 11:30 am	Biospecimen Resources for the Research Community: Cooperative Human Tissue Network, NCI National Clinical Trials Network and Specimen Resource Locator	Irina A. Lubensky, M.D. Aniruddha Ganguly, Ph.D. Cancer Diagnosis Program

Staff Kiosk Schedule – Exhibit Booth #1319

Date	Time	Presenter
April 07	1:00 - 3:00 pm	Aniruddha Ganguly, Ph.D. Cancer Diagnosis Program
	3:00 - 5:00 pm	Christophe Marchand, Ph.D. Developmental Therapeutics Program
April 08	9:00 - 11:00 am	Morgan O’Hayre, Ph.D. Developmental Therapeutics Program
	11:00 - 1:00 pm	Yali Fu, Ph.D. Developmental Therapeutics Program
	1:00 - 3:00 pm	Sharad Verma, Ph.D. Developmental Therapeutics Program
	3:00 - 5:00 pm	Beverly Teicher, Ph.D. Developmental Therapeutics Program
April 09	9:00 - 11:00 am	Ana Robles, Ph.D. Office of Cancer Clinical Proteomics Research
	11:00 - 1:00 pm	Aniruddha Ganguly, Ph.D. Cancer Diagnosis Program
	1:00 - 3:00 pm	Sundar Venkatachalam, Ph.D. Developmental Therapeutics Program
	3:00 - 5:00 pm	Christophe Marchand, Ph.D. Developmental Therapeutics Program
April 10	9:00 - 12:30 pm	Aniruddha Ganguly, Ph.D. Cancer Diagnosis Program